English | Español

Regulatory
+ Regulatory
Press release submission | Jan 5, 2022

NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
+ Regulatory
Bree Gonzales | Jan 5, 2022

Biden: 'We’re mobilizing an additional 1,000 military doctors and nurses to help staff hospitals'
+ Regulatory
Bree Gonzales | Jan 4, 2022

The No Surprises Act took effect Jan. 1: 'Its effect will eventually be felt by literally everybody'
+ Community
Press release submission | Jan 4, 2022

Depression screening improves care for patients with cancer
+ Regulatory
Bree Gonzales | Jan 4, 2022

Vaccine mandate for domestic air travel is not off the table: 'You want to keep people safe'
+ Regulatory
Bree Gonzales | Jan 3, 2022

Health experts challenge CDC’s new isolation guidelines despite 'sheer volume of new cases'
+ Regulatory
Press release submission | Dec 29, 2021

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
+ Regulatory
Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation